misterla.blogg.se - Andexanet

Gómez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fernández AI, Suárez-Gea ML, Lecumberri R, et al.

Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. 2017 377(5):431–41.įanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, França LR, Reilly PA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Praxbind (idarucizumab): Prescribing Information. Praxbind (idarucizumab): Summary of Product Characteristics. This is one of the most important guidelines addressing reversal agents for DOACs.Įuropean Medicines Agency (EMA). Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al.

Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E. Effect of vitamin K upon hypopothrombinemia induced by dicumarol in man. The antihaemorrhagic vitamin of the chick.: occurrence and chemical nature.

Discovery of anticoagulant drugs: a historical perspective. Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernández C, et al. Papers of particular interest, published recently, have been highlighted as:

Specific reversal agents are recommended for use in clinical situations within their licensed indications (i.e.: reversal of DOACs in patients with severe uncontrolled or life-threatening bleeding or in need of emergency surgery or other invasive procedures), while non-specific reversal agents may be used when specific antidotes are not available or indicated. New investigational antidotes such as ciraparantag and VMX-C001 offer an alternative to andexanet alfa in reversing the anticoagulant activity of direct oral factor Xa inhibitors, but more clinical data are needed before they could be licensed for use. Specific (idarucizumab for dabigatran and andexanet alfa for direct factor Xa inhibitors) and non-specific (prothrombin complex concentrates) reversal agents are effective in neutralizing the anticoagulant effect of DOACs.

Our objective is to describe currently available reversal agents for direct oral anticoagulants (DOACs), their target population, the available clinical practice recommendations and future directions.